# CRYBG2

## Overview
CRYBG2, or crystallin beta-gamma domain containing 2, is a gene that encodes a protein belonging to the βγ-crystallin superfamily, which is primarily recognized for its structural role in ocular tissues. The protein encoded by CRYBG2 is involved in maintaining cellular structural integrity and responding to stress, with significant functions in stabilizing cytoskeletal filaments and preventing the aggregation of macromolecular complexes. While it is predominantly associated with the lens and retina, where it contributes to transparency and light transmission, CRYBG2 is also expressed in other tissues, such as the brain, suggesting a broader role in cellular architecture and homeostasis. The protein's structural features, including β-crystallin-like domains and a C-terminal trefoil domain, indicate its involvement in actin filament organization, which may extend its functional significance beyond ocular tissues (Slingsby2014Functions).

## Function
CRYBG2, or crystallin beta-gamma domain containing 2, is a gene that encodes a protein involved in maintaining cellular structural integrity and stress response. The protein is part of the βγ-crystallin superfamily, which is known for its role in stabilizing cytoskeletal filaments and preventing the aggregation of macromolecular complexes, particularly in the lens and retina. This function is crucial for maintaining transparency and efficient light transmission in ocular tissues (Slingsby2014Functions).

Although CRYBG2 is primarily associated with the lens, it is also expressed in other tissues, such as the brain, where it may help maintain normal trafficking networks and prevent aggregation in neurons and other long-lived cells (Slingsby2014Functions). The protein contains β-crystallin-like domains and a C-terminal trefoil domain, which are potentially involved in actin filament organization, suggesting a role in cellular architecture beyond the lens (Slingsby2014Functions).

While the specific molecular activities of CRYBG2 in healthy human cells are not fully detailed, its structural features and domain organization imply a role in cellular stability and protection against stress-induced damage, contributing to the overall maintenance of cellular homeostasis (Slingsby2014Functions).

## Clinical Significance
CRYBG2 (crystallin beta-gamma domain containing 2) has been implicated in several diseases due to mutations and alterations in its expression. In metaplastic breast carcinoma (MBC), a subtype of triple-negative breast cancer, CRYBG2 mutations were identified in 40% of the cases studied. These mutations are part of a broader investigation into the genetic and proteomic profiles of MBC, which is known for its aggressive behavior and chemoresistance (Djomehri2020Quantitative).

CRYBG2 is also involved in epithelial-mesenchymal transition (EMT) and signaling pathways such as TGF-beta and WNT in urothelial carcinoma, particularly in tumors with altered HIF-2 expression. This involvement suggests a role in promoting immune evasion and contributing to the aggressive nature of these tumors (Vlachostergios2022HypoxiaInducible).

In Alzheimer's disease, CRYBG2 was among the proteins with significant differences in expression between patients and controls, indicating its potential involvement in the disease's pathology (Hanas2021Distinguishing). Although specific diseases directly linked to CRYBG2 mutations are not extensively documented, its role in these conditions highlights its clinical significance.


## References


[1. (Djomehri2020Quantitative) Sabra I. Djomehri, Maria E. Gonzalez, Felipe da Veiga Leprevost, Shilpa R. Tekula, Hui-Yin Chang, Marissa J. White, Ashley Cimino-Mathews, Boris Burman, Venkatesha Basrur, Pedram Argani, Alexey I. Nesvizhskii, and Celina G. Kleer. Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors. Nature Communications, April 2020. URL: http://dx.doi.org/10.1038/s41467-020-15283-z, doi:10.1038/s41467-020-15283-z. This article has 75 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-15283-z)

[2. (Hanas2021Distinguishing) Jay S. Hanas, James R. S. Hocker, Christian A. Vannarath, Megan R. Lerner, Scott G. Blair, Stan A. Lightfoot, Rushie J. Hanas, James R. Couch, and Linda A. Hershey. Distinguishing alzheimer’s disease patients and biochemical phenotype analysis using a novel serum profiling platform: potential involvement of the vwf/adamts13 axis. Brain Sciences, 11(5):583, April 2021. URL: http://dx.doi.org/10.3390/brainsci11050583, doi:10.3390/brainsci11050583. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/brainsci11050583)

[3. (Vlachostergios2022HypoxiaInducible) Panagiotis Vlachostergios, Ioannis Tamposis, Maria Anagnostou, Maria Papathanassiou, Lampros Mitrakas, Ioannis Zachos, Eleni Thodou, Maria Samara, and Vassilios Tzortzis. Hypoxia-inducible factor-2-altered urothelial carcinoma: clinical and genomic features. Current Oncology, 29(11):8638–8649, November 2022. URL: http://dx.doi.org/10.3390/curroncol29110681, doi:10.3390/curroncol29110681. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/curroncol29110681)

[4. (Slingsby2014Functions) Christine Slingsby and Graeme J. Wistow. Functions of crystallins in and out of lens: roles in elongated and post-mitotic cells. Progress in Biophysics and Molecular Biology, 115(1):52–67, July 2014. URL: http://dx.doi.org/10.1016/j.pbiomolbio.2014.02.006, doi:10.1016/j.pbiomolbio.2014.02.006. This article has 77 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pbiomolbio.2014.02.006)